Results(4629)
Long-term outcomes in patients treated with ADVAGRAF following standard criteria donor or expanded criteria donor kidney transplant in routine clinical practice in Europe: a multicenter secondary data (chart review) cohort study
France
Germany
Spain
EU PAS number:
EUPAS1000000589
First published:
15/04/2026
Study
Ongoing
Long-term outcomes in patients continuously treated with ADVAGRAF following a liver transplant in routine clinical practice in Spain: a multicenter secondary data (chart review) cohort study
Spain
EU PAS number:
EUPAS1000000603
First published:
15/04/2026
Study
Ongoing
The Mycophenolate Pregnancy Registry
United States
EU PAS number:
EUPAS10541
First published:
15/04/2026
Study
Ongoing
Belzutifan special drug use results survey in von Hippel-Lindau (VHL) disease-associated tumors: a post-authorization safety study (PASS) (MK-6482-046)
Japan
EU PAS number:
EUPAS1000000881
First published:
15/04/2026
Study
Planned
Post-authorisation safety study (PASS) to evaluate risk minimisation measures for medication errors with Uptravi during the titration phase in patients with pulmonary arterial hypertension (PAH) in clinical practice (EDUCATE)
Germany
Greece
Italy
Poland
Spain
United Kingdom
EU PAS number:
EUPAS25699
First published:
15/04/2026
Study
Ongoing
Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either UPTRAVI (selexipag) or any other PAH-specific therapy, in clinical practice (EXPOSURE)
Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Ireland
Italy
Lithuania
Netherlands
Poland
Portugal
Russian Federation
Slovakia
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS19085
First published:
15/04/2026
Study
Ongoing
Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)
Portugal
EU PAS number:
EUPAS1000000414
First published:
15/04/2026
Study
Ongoing
European Sickle Cell Disease Cohort – Hydroxyurea – Extension study (ESCORT-HU Extension)
France
Germany
Greece
Italy
EU PAS number:
EUPAS1000000066
First published:
15/04/2026
Study
Finalised
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
United States
EU PAS number:
EUPAS1000000922
First published:
15/04/2026
Study
Ongoing
Observational study to assess effectiveness of ROTATEQ® against acute gastroenteritis (AGE) due to rotavirus (regardless of type) and by type in China
China
EU PAS number:
EUPAS1000000734
First published:
14/04/2026
Study
Ongoing
Nested case-control study evaluating effectiveness of immunization of girls and women of childbearing potential with GARDASIL(TM)/GARDASIL(TM) 9 against juvenile-onset recurrent respiratory papillomatosis (JoRRP) in Sweden, Denmark, and Norway (V503-095)
Denmark
Norway
Sweden
EU PAS number:
EUPAS1000000286
First published:
14/04/2026
Study
Ongoing
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)
Brazil
Canada
Czechia
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
United States
EU PAS number:
EUPAS49827
First published:
14/04/2026
Study
Finalised
A Nested Case-Control Post-Authorization Effectiveness Study: The Association Between Prior Exposure to Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and Dengue Hospitalization in a Pediatric and Adolescent Population
Indonesia
Malaysia
Thailand
EU PAS number:
EUPAS1000000218
First published:
14/04/2026
Study
Ongoing
POST AUTHORIZATION SAFETY STUDY OF FEXINIDAZOLE FOR HUMAN AFRICAN TRYPANOSOMIASIS : Analysis of real-life safety and effectiveness data on fexinidazole, collected by NSSCP & WHO as part of NSSCP activity as per WHO interim guidelines 2019 (FEXINC09395)
Anguilla
Burkina Faso
Cameroon
Central African Republic
Chad
Congo
Congo, The Democratic Republic of the
Côte d’Ivoire
Equatorial Guinea
Gabon
Ghana
Guinea
Mali
Nigeria
South Sudan
Uganda
EU PAS number:
EUPAS37342
First published:
14/04/2026
Study
Finalised
DARWIN EU® - Drug utilisation study of intramuscular depot olanzapine
Croatia
Denmark
Germany
Hungary
Sweden
EU PAS number:
EUPAS1000000980
First published:
14/04/2026
Study
Ongoing
Observational study to investigate safety and effectiveness of lorlatinib as first line treatment for ALK-gene rearranged unresectable advanced/recurrent NSCLC patients in Japan clinical setting
Japan
EU PAS number:
EUPAS1000000117
First published:
13/04/2026
Study
Ongoing
A Post-Authorization Safety Study (PASS) to Characterize Safety Events and Special Conditions, Such as Pregnancy and Infant Outcomes, in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Crovalimab Within the IPIG Registry
Belgium
Canada
France
Germany
Italy
Korea, Republic of
Netherlands
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000702
First published:
13/04/2026
Study
Planned
Unidade Local de Saúde São João (ULSSJ)
Portugal
First published:
13/04/2026
Institution
Hospital/Clinic/Other health care facility
Tumour Lysis Syndrome Associated with Lenvatinib: an Investigator-Initiated, Retrospective Observational Post-Authorisation Safety Study (TELSTAR)
Portugal
EU PAS number:
EUPAS1000000977
First published:
13/04/2026
Study
Planned
A Post-marketing, Observational Safety Study of Quinsair (Levofloxacin Hemihydrate) in Patients with Cystic Fibrosis [CLI-LEVFLAA1-01]
Germany
United Kingdom
EU PAS number:
EUPAS20990
First published:
13/04/2026
Study
Finalised
Description and assessment of fitness-for-purpose of real-world data (RWD) sources on Duchenne Muscular Dystrophy for regulatory decision-making
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
China
Croatia
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
India
Iran, Islamic Republic of
Italy
Japan
Netherlands
New Zealand
Poland
Portugal
Russian Federation
Saudi Arabia
Serbia
South Africa
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000748
First published:
13/04/2026
Study
Ongoing
Human genetics of myocarditis: overall, after mRNA COVID-19 vaccination, and after SARS-CoV-2 infection
United States
EU PAS number:
EUPAS1000000728
First published:
10/04/2026
Study
Ongoing
The Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update
Canada
EU PAS number:
EUPAS107333
First published:
10/04/2026
Study
Finalised
CAB LA PrEP Cohort: Prospective Cohort Study to Assess Adherence and Effectiveness of, and Monitor for Hepatotoxicity and Resistance to, Cabotegravir for Pre-Exposure Prophylaxis in Europe (221935)
Belgium
France
Ireland
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000299
First published:
09/04/2026
Study
Planned
A Post-Marketing Safety Study to Evaluate the Safety of VELSIPITY® (Etrasimod) Exposure During Pregnancy (C5041043)
Canada
United States
EU PAS number:
EUPAS1000000672
First published:
09/04/2026
Study
Planned
Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)
China
EU PAS number:
EUPAS1000000758
First published:
09/04/2026
Study
Planned
Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant
Argentina
Bolivia, Plurinational State of
Chile
El Salvador
Germany
Guatemala
Honduras
Mexico
Spain
United States
Uruguay
EU PAS number:
EUPAS1000000884
First published:
09/04/2026
Study
Planned
DARWIN EU® - Neonatal seizures: Incidence, prevalence, patient characterisation, and treatments in European countries
Finland
France
Hungary
Norway
EU PAS number:
EUPAS1000000822
First published:
09/04/2026
Study
Ongoing
Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)
France
Germany
EU PAS number:
EUPAS1000000776
First published:
09/04/2026
Study
Ongoing
Bimekizumab Pregnancy Exposure and Outcome Registry: An OTIS Autoimmune Diseases in Pregnancy Study
Canada
United States
EU PAS number:
EUPAS1000000968
First published:
09/04/2026
Study
Ongoing
Real-world experience of children with growth hormone deficiency who switched from daily growth hormone to the Long-Acting Growth Hormone Somatrogon
Czechia
Israel
EU PAS number:
EUPAS1000000829
First published:
09/04/2026
Study
Ongoing
Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000789
First published:
09/04/2026
Study
Finalised
A Non-Interventional Study (NIS) PASS to characterize secondary malignancies of T-cell origin following tisagenlecleucel therapy (CCTL019B2402)
Australia
Austria
Brazil
Canada
Czechia
France
Germany
Hong Kong
Israel
Italy
Japan
Korea, Republic of
Netherlands
Poland
Russian Federation
Saudi Arabia
Singapore
Spain
Switzerland
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS1000000749
First published:
08/04/2026
Study
Ongoing
A regulatory requirement non-interventional study to monitor the safety and effectiveness of Spesolimab in Korean patients with flares with generalized pustular psoriasis
Korea, Republic of
EU PAS number:
EUPAS1000000278
First published:
08/04/2026
Study
Discontinued
Real-world Persistency, Effectiveness, and Safety Among Patients with NMOSD Treated with Inebilizumab (20250110)
United States
EU PAS number:
EUPAS1000000958
First published:
08/04/2026
Study
Ongoing
An Observational Registry-Based Study to Evaluate the Long-Term Safety of Tofersen in People With SOD1-ALS
United States
EU PAS number:
EUPAS1000000365
First published:
08/04/2026
Study
Ongoing
Post-marketing Safety Study of mRNA-1283 in the United States
United States
EU PAS number:
EUPAS1000000971
First published:
08/04/2026
Study
Planned
A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection (208165)
Netherlands
United Kingdom
EU PAS number:
EUPAS37605
First published:
08/04/2026
Study
Ongoing
DARWIN EU® - Assessing the potential association between venlafaxine and heart failure in adults
Denmark
Finland
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000974
First published:
08/04/2026
Study
Ongoing
Compare data sources